Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Presents Scaled-Down Remote-Monitoring Legislation

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed has given the Senate Finance Committee a scaled-down version of legislation to promote remote-monitoring devices that it hopes will be included in a Medicare package being shaped in Congress this year

You may also be interested in...



Medicare Bill Becomes Law: Industry Focuses On What Didn’t Make the Cut

A Medicare bill made law last week was of interest to device firms as much or more for what it did not contain than for what it did include

Medicare Bill Becomes Law: Industry Focuses On What Didn’t Make the Cut

A Medicare bill made law last week was of interest to device firms as much or more for what it did not contain than for what it did include

Remote monitoring bill

Rep. Anna Eshoo, D-Calif., introduces April 10 legislation requiring CMS to reimburse doctors for time spent analyzing data sent remotely from patient devices. The Medicare Remote Monitoring Access Act (1H.R. 5765) would cover remote patient management services for heart failure and cardiac arrhythmia, effective on Jan. 1, 2010. A two-year, three-site demonstration project would evaluate the impact and benefits of covering remote monitoring of beneficiaries with diabetes, epilepsy and sleep apnea devices, the bill says (2"The Gray Sheet" Nov. 5, 2007, p. 5)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel